XtalPi and Pfizer Expand Partnership to Advance AI-Driven Drug Discovery and Materials Simulation

XtalPi has expanded its collaboration with Pfizer to develop an advanced AI-powered molecular modeling platform, aiming to improve the speed and accuracy of small-molecule drug discovery by combining physics-based methods with scalable AI tools Under the expansion, XtalPi and Pfizer will develop predictive models tailored to Pfizer’s chemical space, enhancing small-molecule drug discovery. XtalPi will…

ByDipanshu Dixit1 day ago

News

Vor Bio Enters a ~$4.12B Exclusive Global License Agreement with RemeGen to Develop and Commercialize Telitacicept

Shots: Vor Bio and RemeGen have entered an exclusive licensing agreement, giving Vor Bio rights outside China, Hong Kong, Macau, and Taiwan to develop & commercialize telitacicept As per the Deal, RemeGen will receive $125M ($45M upfront and $80M in stock warrants). RemeGen is eligible for more than $4B in regulatory & commercial milestones + tiered…

ByDipanshu Dixit4 days ago

News

mAbxience and Abiogen Pharma Enter into a Strategic Licensing Agreement for Biosimilar across Italy

Shots: mAbxience, majority-owned by Fresenius Kabi and partially by Insud Pharma, has partnered with Abiogen Pharma in a strategic licensing agreement to develop & commercialize a biosimilar in Italy As per the agreement, mAbxience will hold marketing authorization, while Abiogen Pharma handles commercialization and marketing in Italy This collaboration leverages mAbxience’s biosimilar development expertise and…

ByDipanshu DixitMay 26, 2025

EXCLUSIVE

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots: Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM) Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma In late 2022,…

BySaurabh ChaubeySeptember 30, 2024

VIEWPOINTS

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Shots: Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds. QurAlis received an up front payment of $45M plus an additional equity investment. The company is…

BySaurabh ChaubeySeptember 2, 2024

XtalPi and Pfizer Expand Partnership to Advance AI-Driven Drug Discovery and Materials Simulation

Vor Bio Enters a ~$4.12B Exclusive Global License Agreement with RemeGen to Develop and Commercialize Telitacicept

mAbxience and Abiogen Pharma Enter into a Strategic Licensing Agreement for Biosimilar across Italy

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Contact US

OUR INFORMATION

FOLLW US

XtalPi and Pfizer Expand Partnership to Advance AI-Driven Drug Discovery and Materials Simulation

Vor Bio Enters a ~$4.12B Exclusive Global License Agreement with RemeGen to Develop and Commercialize Telitacicept

mAbxience and Abiogen Pharma Enter into a Strategic Licensing Agreement for Biosimilar across Italy

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

FOLLW US

Sign Up to Our Newsletter